Nestlé invests $ 1.4 billion in skin care

Nestle announced the acquisition of the rights of various products of the Canadian Dermatology Valeant Pharmaceuticals International for $ 1.4 billion to boost your skin care business. The purchase gives Nestle the right to market in the United States and in Canada the products Restylane, Perlane and Emervel, used for corrective Facial cosmetic treatments, besides the Dysport, a dermatological cosmetic treatment and Sculptra, dermal filler used in medical and cosmetic. Recently the company also assumed Switzerland joint venture of Dermatology Galderma in partnership with L'oreal. (Reuters)